Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

GfK Healthcare's Roper Global Diabetes Program Launches New U.S. Diabetes Patient Market Study
GfK Healthcare"s Roper Global Diabetes Program, the definitive global perspective on diabetes, announced today the launch of its enhanced U.S. Diabetes Patient Market Study. Through a modular approach and with tailored reporting, the study offers health care and related companies in the diabetes category access to patient data and market trends from one of the largest surveys of people with diabetes, and the only one projectable to the U.S. population.
generic viagra online
Doctors And Hospitals Look For Ways To Cut Costs, Improve Quality
The "patient-centered" practices movement is growing in popularity, the New York Times reports. Primary care physicians in the practices "spend more time with patients, emphasize prevention and education" to keep patients healthy and "can handle many medical problems without referrals to specialists." Often, "this kind of care can reduce a patient"s medical bills." Dr. Jose Batlle, a doctor in the Bronx, for example, gives patients his cell phone number and helps his patients cut down on the number of prescription drugs that have him prescribed to them by multiple specialists. "I prefer to keep them healthy than treat them when they are sick," Batlle says.
plastic surgery before after
News of the day
How To Confirm The Causes Of Iron Deficiency Anemia In Young Women
Iron-deficiency anaemia (IDA) is commonly seen in women aged under 50 years. The diagnostic workflow in young women affected by IDA is not clearly established. The British Society of Gastroenterology recommends gastroscopy only in IDA women younger than 45 years presenting with gastrointestinal (GI) symptoms. However, symptoms are often mild and aspecific in IDA women and the gastroscopy is an invasive procedure associated with a high number of refusals. In a previous work on IDA premenopausal women, gastroscopy was performed in all patients, later deemed unnecessary in almost 30% of the studied women because these were affected only by menorrhagia.
Sexual Health

Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT™ Falcon At EuroPCR

Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain. This is one of the first drug-eluting balloons designed specifically to treat atherosclerosis in the coronary arteries and underscores Invatec"s commitment to robust scientific research into the reduction of re-intervention rates in the treatment of Coronary Artery Disease (CAD). Prof. Eberhard Grube, Chief, Department of Cardiology/Angiology at the Heart Center, Siegburg, Germany, commented, "Combining world-class PTCA balloon catheter technology with local drug administration is a fascinating new concept for the treatment of certain coronary lesions such as In-Stent Restenosis (ISR), Small Vessel Disease (SVD), Bifurcations and potentially other lesions where conventional balloons, stents and even drug eluting stents may not be ideal. A drug eluting balloon such as the IN.PACT Falcon that elutes a known and effective drug such as Paclitaxel holds much promise as an effective treatment option for patients." IN.PACT Falcon combines the currently marketed, performance leading Falcon line of PTCA balloon catheters with Invatec"s proprietary IN.PACT technology platform and FreePac™ coating. FreePac is a proprietary, natural coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery. The FreePac coating was developed in close collaboration with the researchers who pioneered drug-eluting balloon therapy, Ulrich Speck, Ph.D., Department of Radiology at Charite Mitte, Berlin and Bruno Scheller, M.D., University Hospital, Department of Internal Medicine, Homburg/Saar. "We are extremely excited to commercialize a much-needed product that combines our FreePac coating technology with the performance-leading characteristics of our Falcon PTCA balloon platform, thereby creating a world class drug eluting balloon," commented Andrea Venturelli and Stefan Widensohler, co-founders of Invatec. "The European availability of IN.PACT Falcon underscores our mission to provide physicians with the option of using drug eluting balloons for specific clinical indications throughout the coronary and peripheral anatomy. The launch of IN.PACT Falcon also aligns with our strategy to leverage FreePac on all of our major balloon platforms. We see an immediate opportunity for the IN.PACT Falcon to treat patients with In Stent Restenosis (ISR) and plan to proceed with an ambitious clinical research program to further study the use of IN.PACT Falcon to treat Small Vessel Disease and de novo lesions. " Invatec


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009